awmsg logo



parathyroid hormone (Preotact®)


Reference No. 237

Publication date:
10/08/2007


Appraisal information

parathyroid hormone (Preotact®) 100 micrograms powder and solvent for solution for injection


Company: Nycomed UK Ltd
BNF category: Endocrine system
NMG meeting date: 17/05/2007
AWMSG meeting date: 12/06/2007
   
   
Submission Type: Full Submission
Status: Recommended with restrictions
Advice No: 0307
Ministerial ratification: 30/07/2007

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Parathyroid hormone (Preotact®) is recommended for restricted use within NHS Wales for the treatment of postmenopausal women with osteoporosis at high risk of fractures. It should be considered as an alternative to teriparatide only in patients who are intolerant of that agent, or where the storage or administration issues are deemed to provide significant added benefit. It should only be initiated by specialists experienced in the treatment of osteoporosis.
Final Appraisal Recommendation (FAR)
Download